Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) saw unusually-strong trading volume on Monday. 124,635 shares traded hands during trading, an increase of 14% from the average daily volume of 109,507 shares. The stock last traded at $4.76 and had previously closed at $4.31.
Analyst Ratings Changes
GYRE has been the topic of several analyst reports. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a research note on Wednesday, November 4th. Finally, Wall Street Zen raised Gyre Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce”.
Read Our Latest Analysis on GYRE
Gyre Therapeutics Price Performance
The company has a market capitalization of $547.77 million, a P/E ratio of -23.60 and a beta of 2.14. The company has a 50 day moving average of $6.30 and a 200-day moving average of $6.81.
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.19. The business had revenue of $32.93 million during the quarter, compared to analyst estimates of $28.40 million. Gyre Therapeutics had a negative return on equity of 7.39% and a negative net margin of 14.80%. Research analysts predict that Gyre Therapeutics, Inc. will post -0.61 EPS for the current fiscal year.
Hedge Funds Weigh In On Gyre Therapeutics
Several large investors have recently modified their holdings of the stock. Bank of America Corp DE bought a new position in Gyre Therapeutics in the 2nd quarter valued at approximately $83,000. Deutsche Bank AG bought a new stake in shares of Gyre Therapeutics in the 2nd quarter worth $118,000. Dimensional Fund Advisors LP raised its stake in shares of Gyre Therapeutics by 131.8% in the first quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock worth $176,000 after purchasing an additional 14,365 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Gyre Therapeutics by 4.7% in the first quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company’s stock worth $301,000 after purchasing an additional 1,941 shares during the last quarter. Finally, SBI Securities Co. Ltd. lifted its holdings in shares of Gyre Therapeutics by 1.8% during the third quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company’s stock valued at $1,244,000 after purchasing an additional 2,967 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.
Gyre Therapeutics Company Profile
Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.
Read More
- Five stocks we like better than Gyre Therapeutics
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
